The clinical metrics gathered over the open-label phase lasting up to 10 years (during which most of patients remained under continuous IFN-b therapy, or were shifted to the DMT that their neurologist in charge considered indicated) were also comparable between the two groups, suggesting that beginning IFN therapy with a cyclic dose variation should not affect the long-term clinical progression of MS. This evidence concerns the gene IFNB1 and myeloid sarcoma.